Cabot Wealth Management Inc. acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 8,741 shares of the company’s stock, valued at approximately $1,359,000.

A number of other hedge funds also recently made changes to their positions in IDXX. FMR LLC lifted its position in IDEXX Laboratories by 1,293.2% in the first quarter. FMR LLC now owns 36,419 shares of the company’s stock valued at $5,630,000 after purchasing an additional 33,805 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of IDEXX Laboratories by 20.6% during the first quarter. Dimensional Fund Advisors LP now owns 326,957 shares of the company’s stock valued at $50,550,000 after acquiring an additional 55,939 shares in the last quarter. Fox Run Management L.L.C. raised its holdings in shares of IDEXX Laboratories by 20.0% during the second quarter. Fox Run Management L.L.C. now owns 3,000 shares of the company’s stock valued at $484,000 after acquiring an additional 500 shares in the last quarter. Gateway Investment Advisers LLC raised its holdings in shares of IDEXX Laboratories by 8.1% during the second quarter. Gateway Investment Advisers LLC now owns 7,976 shares of the company’s stock valued at $1,287,000 after acquiring an additional 601 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. raised its holdings in shares of IDEXX Laboratories by 722.2% during the second quarter. NN Investment Partners Holdings N.V. now owns 4,933 shares of the company’s stock valued at $796,000 after acquiring an additional 4,333 shares in the last quarter. Hedge funds and other institutional investors own 87.71% of the company’s stock.

In other news, CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $153.75, for a total value of $2,767,500.00. Following the sale, the chief executive officer now directly owns 1,064,573 shares of the company’s stock, valued at $163,678,098.75. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Jonathan W. Ayers sold 54,000 shares of the stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $151.32, for a total value of $8,171,280.00. Following the completion of the sale, the chairman now directly owns 1,064,573 shares in the company, valued at $161,091,186.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 188,734 shares of company stock worth $28,954,266. Insiders own 2.77% of the company’s stock.

A number of equities analysts recently commented on IDXX shares. Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Stifel Nicolaus restated a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a report on Monday, August 21st. Canaccord Genuity restated a “buy” rating and set a $180.00 target price on shares of IDEXX Laboratories in a report on Tuesday, August 22nd. BidaskClub downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target on the stock in a research note on Friday, July 28th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $173.67.

TRADEMARK VIOLATION WARNING: “Cabot Wealth Management Inc. Takes $1.36 Million Position in IDEXX Laboratories, Inc. (IDXX)” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/11/12/cabot-wealth-management-inc-takes-1-36-million-position-in-idexx-laboratories-inc-idxx.html.

Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) traded down $2.51 during mid-day trading on Friday, reaching $147.68. The company had a trading volume of 525,000 shares, compared to its average volume of 557,359. The stock has a market capitalization of $12,880.50, a PE ratio of 49.72, a price-to-earnings-growth ratio of 2.23 and a beta of 0.46. IDEXX Laboratories, Inc. has a 12 month low of $107.59 and a 12 month high of $173.01. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. During the same period in the prior year, the firm posted $0.62 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. equities research analysts predict that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.